Why the study?
Does combined treatment with antithrombin substitution and low-molecular-weight heparin prevent pregnancy loss and thromboembolism in a pregnant patient with antithrombin deficiency?
Does combined treatment with antithrombin substitution and low-molecular-weight heparin prevent pregnancy loss and thromboembolism in a pregnant patient with antithrombin deficiency?
Combined antithrombin substitution and low-molecular-weight heparin may enable successful pregnancy in patients with severe antithrombin deficiency and recurrent miscarriages.
May support combined antithrombin and LMWH in severe deficiency with recurrent loss; hypothesis-generating and should not yet change practice.
Inherited thrombophilias are associated with an increased risk of maternal thromboembolism and certain adverse pregnancy outcomes, including second- and third-trimester fetal loss, placental abruption, severe intrauterine growth restriction, and early-onset, severe preeclampsia. Pregnant patients with severe thrombophilias, especially antithrombinopathies are at very high risk for both thromboembolism and adverse pregnancy outcomes. A case of a patient with antithrombin deficiency is reported, who had two successful pregnancies after eight miscarriages. Our case shows that a combined treatment with antithrombin substitution and a prophylactic, body-weight-adjusted dose of low-molecular-weight heparin may be successful in preventing pregnancy loss and thromboembolism in antithrombin deficiency during pregnancy, although other complications, such as preeclampsia and intrauterine growth restriction cannot always be prevented.
No takes yet. Share an insight, caveat, or question.
Szilágyi et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: